In an encouraging development in HIV prevention, a significant breakthrough has been made with lenacapavir, a long-acting drug that could potentially offer robust protection against HIV infections. In a recent clinical trial, the drug achieved a remarkable 100% prevention rate among women and girls, and it demonstrated safety—being administered only twice annually.
Currently approved for treating HIV, lenacapavir’s efficacy in prevention is now being studied. At a conference in San Francisco, a small phase I trial presented promising initial safety results for a once-yearly injection of lenacapavir. As these findings progress, the possibility of an easier and more effective prevention measure could become a pivotal advancement in the fight against HIV.
Source: Read more